Keros Therapeutics (KROS) EBT (2019 - 2025)

Keros Therapeutics has reported EBT for 7 years, with the latest figure at -$25.0 million in Q4 2025.

• For the quarter ending Q4 2025, EBT rose 45.38% year-over-year to -$25.0 million; the trailing twelve-month figure through Dec 2025 stood at $91.9 million (up 149.13% YoY), and the FY2025 full-year result was $91.9 million, up 149.13% from the prior year.
• EBT for Q4 2025 stood at -$25.0 million, down from -$8.7 million in the prior quarter.
• The five-year high for EBT was $158.5 million in Q1 2025, with the low at -$53.0 million in Q3 2024.
• Historically, EBT has averaged -$21.3 million across 5 years, with a median of -$28.5 million in 2022.
• Annual changes were most pronounced in 2022 — EBT plunged 501.46% — and 2025, when it surged 467.62%.
• Keros Therapeutics' EBT stood at -$4.9 million in 2021, then sank by 501.46% to -$29.7 million in 2022, then plunged by 56.32% to -$46.5 million in 2023, then increased by 1.57% to -$45.7 million in 2024, then soared by 45.38% to -$25.0 million in 2025.
• The last three EBT figures came in at -$25.0 million (Q4 2025), -$8.7 million (Q3 2025), and -$32.9 million (Q2 2025), per Business Quant data.